For Immediate Release
Chicago, IL – October 14, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Allscripts-Misys Healthcare Solutions, Inc. (MDRX), Intuit Inc. (INTU), Cerner Corporation (CERN), Quality Systems Inc. (QSII) and MedAssets Inc. (MDAS).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Tuesday’s Analyst Blog:
Allscripts Aligns with Quicken
Allscripts-Misys Healthcare Solutions, Inc. (MDRX) recently entered in an alliance with Intuit Inc. (INTU), a leading provider of business and financial management solutions, to offer Quicken Health Bill Pay.
This is the first online service that integrates with Allscripts’ practice management and revenue cycle management solutions. As the name indicates, the system helps explain patients their medical bills and enable them to pay online while helping physicians get paid faster.
Quicken Health Bill Pay alerts patients more quickly that a payment is due. The system displays how the amount due was calculated in simple mathematics and provides accurate data. The system quickens the patient bill payment process by an average of 18 days compared to the traditional way of using paper check. It also reduces the cost of collection incurred in the traditional process.
It’s been observed that many physician practices write off roughly 50% of their patient payments as bad debt. Of this, approximately 40% of patients don’t pay their bills because either they don’t understand them or they doubt the integrity of the amount provided in the bill. This resulted in huge loss to these physicians’ practices. Quicken Health Bill Pay eliminates all these limitations.
The electronic payment facility has huge potential. It’s been estimated that the direct out-of-pocket payments from patients to providers are expected to total $660 billion by 2013.
We think that the new system will be widely accepted by physicians. This will boost demand for the new product and will expand Allscripts’ top-line.
Libertyville, IL-based Allscripts-Misys Healthcare Solutions, Inc. is a leading provider of clinical software and information solutions for physicians. In Oct. 2008, Allscripts merged with Misys Plc, a global applications software and services company, to form Allscripts-Misys Healthcare Solutions, Inc.
Allscripts faces strong competition from Cerner Corporation (CERN), Quality Systems Inc. (QSII) and MedAssets Inc. (MDAS). Based on the first quarter of fiscal 2010, we have assigned a ‘Neutral’ recommendation to Allscripts’ stock.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Web Content Editor